Apply now to become an ISTAART Ambassador
Apply to the ISTAART Ambassador Program to gain mentoring conference experience and a supportive network that helps early career researchers grow.
The Alzheimer's Association leads the way to end Alzheimer's and all other dementia — by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support.
Apply to the ISTAART Ambassador Program to gain mentoring conference experience and a supportive network that helps early career researchers grow.
A guide to preparing and submitting abstracts for AAIC covering structure themes review steps and tips to help you present your research at the conference.
Submit your AAIC 2026 abstract and share your research in London with a global community in Alzheimer and dementia science ready to hear your latest work.
The Alzheimer’s Association Summer Research Institute, Chicago, 3–7 Aug 2026. A free mentoring and training opportunity for early career dementia researchers.
Walking and other healthy habits may benefit people with high genetic risk for Alzheimer’s most, with consistent walking for two years boosting cognition up to 7 yrs later.
Common blood pressure, cholesterol and diabetes drugs taken together linked to slower cognitive decline, with triple therapy showing the strongest brain health benefits.
SNAP food assistance linked to slower cognitive decline over 10 years, suggesting nutrition support may help protect brain health and delay dementia onset in older adults.
Alzheimer’s Association clinical guideline for blood biomarker tests to aid faster, more accurate Alzheimer’s diagnosis in specialised memory care settings.
U.S. POINTER trial shows structured lifestyle changes can boost cognition and protect brain health in at-risk older adults, with benefits lasting up to 2 yrs
Historic lead exposure from the era of leaded petrol linked to 20% higher risk of memory problems in older adults, decades after initial exposure
Real world data from AAIC 2025 shows Alzheimer’s drugs lecanemab and donanemab match or exceed clinical trial safety, with patients reporting positive outcomes.
AAIC 2025 research finds TBIs may shrink dementia-related brain areas more in women and links chemotherapy-related brain changes to memory and focus problems.